Emcure Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Emcure Pharmaceuticals has announced the price revision of its weight management drug Poviztra? (semaglutide injection) across India.

The reduced price would be starting at Rs. 3,999/- per month (4 weekly doses).

The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing.

As the first Indian company to exclusively distribute and commercialise Poviztra?, a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy at the revised price.

Emcure Pharmaceuticals announced the signing of a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. The agreement marks a significant step toward expanding patient access to critical therapies in chronic kidney disease (CKD), anemia management, and transplant care across India. Under the agreement, which will be effective 01 April 2026, Emcure will distribute Roche's established and globally recognised brands in the nephrology and transplant segment in India.

The agreement includes the following brands:

• CellCept? - A globally leading immunosuppressant and original Roche innovation, supporting organ transplants worldwide since 1995.
• Mircera? and Neorecormon? - Proven therapies for anemia in chronic kidney disease, including Mircera's long-acting ESA with dosing once every 2-4 weeks.

Commenting on the agreement, Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals, said, ?This partnership with Roche is a natural extension of Emcure's commitment to improving outcomes in anemia and renal care. Roche's globally trusted innovations strongly complement our existing portfolio and reach. Together, we aim to expand access to these critical therapies and support physicians in delivering op mal care to patients across India.?

Powered by Capital Market - Live News

Net profit of Emcure Pharmaceuticals rose 49.97% to Rs 230.54 crore in the quarter ended December 2025 as against Rs 153.72 crore during the previous quarter ended December 2024. Sales rose 20.42% to Rs 2363.48 crore in the quarter ended December 2025 as against Rs 1962.63 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 4 February 2026.

Powered by Capital Market - Live News